Bepridil

CHEMBL1008 Phase 4 معتمد Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
366.5 g/mol
LogP
5.3
Phase
4

A calcium channel blocker that was used to treat chronic stable angina and certain heart arrhythmias. It works by slowing electrical conduction in the heart and relaxing blood vessels. Due to serious cardiac side effects, including potentially fatal arrhythmias, its use was discontinued in many countries.

الوزن الجزيئي

366,5000 g/mol

LogP

5,30

TPSA

15,70 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

آلية العمل

Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing calcium influx during depolarization. This produces vasodilation, decreased myocardial contractility, and reduced heart rate.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing calcium influx during depolarization. This produces vasodilation, decreased myocardial contractility, and reduced heart rate.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1

InChI

InChI=1S/C24H34N2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3

Molecular Formula

C24H34N2O

HBD / HBA

- / 3

الروابط القابلة للدوران

10

الذرات الثقيلة

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

A calcium channel blocker that was used to treat chronic stable angina and certain heart arrhythmias. It works by slowing electrical conduction in the heart and relaxing blood vessels. Due to serious cardiac side effects, including potentially fatal arrhythmias, its use was discontinued in many countries.

Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing calcium influx during depolarization. This produces vasodilation, decreased myocardial contractility, and reduced heart rate.

Yes, Bepridil is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1008. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 2351. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.